Intellia Therapeutics, Inc. (NTLA) Institutional Ownership

Ownership Summary

Intellia Therapeutics, Inc. (NASDAQ:NTLA) currently has 10 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• Institutional ownership in Intellia Therapeutics edged down to 0.2% in December 2025, compared to 100.4% in September 2025.
• In percentage terms, this reflects as a holdings change of -12.49% quarter on quarter, and a decrease of 96.52% year over year.
• The latest 13F cycle for Intellia Therapeutics reveals that of 10 total investors, 4 funds grew their exposure, whereas 4 reduced theirs and 2 made no changes.
• Collectively, institutional investors decreased their stake in Intellia Therapeutics to 195.67K shares as of December 2025, a change that is down by 27.92K shares quarter on quarter and down 99.03Mn shares year over year.
• The top institutional stake in Intellia Therapeutics as of December 31, 2025 belongs to Elmwood Wealth Management, Inc., which owns 77.92K shares, or 0.07% of the company.
• Among the most significant buyers of Intellia Therapeutics during December 2025 were Green Alpha Advisors, LLC (16.69K), Cyndeo Wealth Partners, LLC (13.57K), HARBOR INVESTMENT ADVISORY, LLC (100), ADIRONDACK TRUST CO (24).
• Leading sellers of Intellia Therapeutics stock in December 2025 included SG Americas Securities, LLC (57.93K), Elmwood Wealth Management, Inc. (135), Versant Capital Management, Inc (125), GAMMA Investing LLC (124).
• The top 10 institutional holders of Intellia Therapeutics for the quarter ending December 2025 included Elmwood Wealth Management, Inc. (77.92K), SG Americas Securities, LLC (73.14K), Cyndeo Wealth Partners, LLC (25.28K), Green Alpha Advisors, LLC (16.69K), Versant Capital Management, Inc (1.57K), GAMMA Investing LLC (418), HARBOR INVESTMENT ADVISORY, LLC (250), MassMutual Private Wealth & Trust, FSB (220), ARMSTRONG ADVISORY GROUP, INC (144), ADIRONDACK TRUST CO (24).